Cardiology

SMART-REACH2 estimates lifetime recurrent-CV risk and treatment gains in established ASCVD

SMART-REACH2 estimates lifetime recurrent CV risk and treatment benefits for patients aged 40–90 with established ASCVD to support shared decision-making. Derived in 8,708 participants and externally validated in 2,085,780 patients across 54 countries, the pooled C-statistic was 0.68. Calibration was adequate across risk regions and CV subtypes, and model outputs include short-term and lifetime absolute benefit estimates. In a 50-year-old example, intensified prevention (SBP −15 mmHg and LDL −1.0 mmol/L) yielded 2 to 4.4 years of CV disease-free life depending on region. 1

Protocol: synthesizing user preferences for wearables in cardiac rehabilitation

This registered systematic-review protocol will synthesize quantitative and qualitative evidence on non-invasive wearables in cardiac rehabilitation. It will examine patient, provider, and caregiver preferences, focusing on comfort, usability, privacy, and trust. The convergent mixed-methods approach aims to integrate thematic qualitative findings with meta-analyzed quantitative results where appropriate. 2

Global survey shows frequent non-labeled sacubitril-valsartan dosing among HF clinicians

In a global IKNOW-HF survey (n=1,285 complete responses from 75 countries), 86.1% of clinicians reported non-labeled sacubitril-valsartan dosing. Non-labeled use was more common among general cardiologists and in low- and lower-middle-income countries; geography and clinician experience predicted practice. Presence of a cardiology pharmacist trended toward fewer non-labeled prescriptions, while HF specialist management trended toward more non-labeled use. 3